Neogenix Oncology announced that the Johns Hopkins Hospital has initiated a Phase I trial with the company’s first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer
GREAT NECK, NY, USA | February 9, 2010 | Neogenix Oncology, Inc. (Neogenix) announced today that the Johns Hopkins Hospital has initiated a Phase I trial with the company’s first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.
NPC-1C is a novel, chimeric monoclonal antibody intended for the treatment of advanced pancreatic and colorectal cancer, and is the first of the Neogenix pipeline of antibodies that target specific cancers. Pre-clinical studies have demonstrated that NPC-1 specifically targets pancreatic and colorectal cancer sparing healthy tissue.
“We are pleased to partner with the investigators at Johns Hopkins on this study and we look forward to fostering the relationship for future Neogenix therapeutic development. There is a serious need for new therapies for life-threatening illnesses, especially pancreatic cancer where very few treatment options exist. Having a treatment that would target the cancer specifically and spare healthy organs would represent a significant advancement in the treatment of this disease,” said Neogenix President and Chief Medical Officer, Philip M. Arlen, MD.
Neogenix Oncology is a cancer therapeutics and diagnostic company focused on developing innovative new products targeting a broad range of cancers. The company’s portfolio includes monoclonal antibodies that have been shown to target tumor-specific immunogenic proteins derived from specific tumor subtypes. Neogenix Oncology monoclonal antibodies are unique in that they define the immunogenic tumor protein as both a diagnostic marker and as a therapeutic target for tumor destruction. This revolutionary approach could offer patients a new range of therapeutic alternatives in the future.
About Neogenix Oncology
Founded in 2004 and headquartered in Great Neck, NY, Neogenix Oncology, Inc., is a research-driven biopharmaceutical company that develops and commercializes innovative therapeutics and diagnostics for the management of solid tumors. Neogenix Oncology’s pipeline is derived in part from the Hollinshead library of clinically tested vaccines, with the potential to develop products for a wide range of cancers, including pancreas, colorectal, prostate, lung, ovarian, squamous, and others. The company conducts its research and development work in its laboratories in Rockville, MD. For general information, please contact Neogenix Oncology at inquiries@neogenix.us. Physicians and patients may request information regarding the clinical trial at www.clinicaltrials.gov.
SOURCE: Neogenix Oncology
Post Views: 76
Neogenix Oncology announced that the Johns Hopkins Hospital has initiated a Phase I trial with the company’s first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer
GREAT NECK, NY, USA | February 9, 2010 | Neogenix Oncology, Inc. (Neogenix) announced today that the Johns Hopkins Hospital has initiated a Phase I trial with the company’s first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.
NPC-1C is a novel, chimeric monoclonal antibody intended for the treatment of advanced pancreatic and colorectal cancer, and is the first of the Neogenix pipeline of antibodies that target specific cancers. Pre-clinical studies have demonstrated that NPC-1 specifically targets pancreatic and colorectal cancer sparing healthy tissue.
“We are pleased to partner with the investigators at Johns Hopkins on this study and we look forward to fostering the relationship for future Neogenix therapeutic development. There is a serious need for new therapies for life-threatening illnesses, especially pancreatic cancer where very few treatment options exist. Having a treatment that would target the cancer specifically and spare healthy organs would represent a significant advancement in the treatment of this disease,” said Neogenix President and Chief Medical Officer, Philip M. Arlen, MD.
Neogenix Oncology is a cancer therapeutics and diagnostic company focused on developing innovative new products targeting a broad range of cancers. The company’s portfolio includes monoclonal antibodies that have been shown to target tumor-specific immunogenic proteins derived from specific tumor subtypes. Neogenix Oncology monoclonal antibodies are unique in that they define the immunogenic tumor protein as both a diagnostic marker and as a therapeutic target for tumor destruction. This revolutionary approach could offer patients a new range of therapeutic alternatives in the future.
About Neogenix Oncology
Founded in 2004 and headquartered in Great Neck, NY, Neogenix Oncology, Inc., is a research-driven biopharmaceutical company that develops and commercializes innovative therapeutics and diagnostics for the management of solid tumors. Neogenix Oncology’s pipeline is derived in part from the Hollinshead library of clinically tested vaccines, with the potential to develop products for a wide range of cancers, including pancreas, colorectal, prostate, lung, ovarian, squamous, and others. The company conducts its research and development work in its laboratories in Rockville, MD. For general information, please contact Neogenix Oncology at inquiries@neogenix.us. Physicians and patients may request information regarding the clinical trial at www.clinicaltrials.gov.
SOURCE: Neogenix Oncology
Post Views: 76
